Compare Levi Strauss & Co. (LEVI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Zimmer Biomet Holdings Inc — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.3× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LEVI | ZBH | |
|---|---|---|
Market Cap | $7.31B | $16.95B |
Volume | 13,683,095 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $103.98 |
52-Week Low | $17.92 | $79.58 |
Typical Hold Time | 70 Days | 89 Days |
Enterprise Value | $8.86B | $24.02B |
Dividend Yield | 3.36% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.70, down 4.15% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.53 and consistent earnings beats, including Q3 2026 EPS of $0.48 versus $0.36 expected. Revenue for 2025 was $6.28 billion with a net income margin of 9.2%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 earnings.
The outlook is positive with a consensus price target of $29.00, implying 55% upside, supported by 78.95% analyst buy ratings. Risks include competitive pressures and recent cybersecurity incidents. The stock's valuation and earnings momentum present a compelling opportunity, though technical weakness warrants monitoring.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
